Product Details
| Product Name:
Tigemonam |
CAS No.:
102507-71-1 |
| Purity:
99.03% |
Supply Ability:
10g |
| Release date:
2026/05/11 |
Product Introduction
Bioactivity
| Name | Tigemonam |
| Description | Tigemonam is a monobactam, a novel orally administered monobactam that protects against gram-negative aerobic bacterial pathogens and is at least as active against clinical isolates of Enterobacteriaceae as amitraz or carmonan (MIC90: 0.06-16 mg/l). [3] |
| In vitro | Tigemonam (0.25 mg/L) inhibits 90% of Escherichia coli, Klebsiella spp., Proteus spp., Salmonella spp., Haemophilus influenzae, and Branhamella catarrhalis. The MIC90 is 16 mg/L for Enterobacter spp. and 4 mg/L for Citrobacter. Pseudomonas aeruginosa is resistant to tigemonam but susceptible to aztreonam. Tigemonam shows minimal inoculum dependence, between 10^2 and 10^6 cfu per spot [1]. |
| In vivo | Tigemonam demonstrates potent efficacy against a range of bacterial strains, including E. coli SC 12199, Escherichia coli SC 8294, Salmonella schottmulleri SC 3850, Proteus mirabilis SC 9575, Providencia rettgeri SC 8217, Klebsiella pneumoniae SC 12216, Serratia marcescens SC 9782, Enterobacter cloacae SC 11078, and Haemophilus influenzae SC 10556, achieving ED50 values of 1.5 mg/kg, 1.4 mg/kg, 0.7 mg/kg, 0.3 mg/kg, 0.2 mg/kg, 0.9 mg/kg, 0.5 mg/kg, 3.9 mg/kg, and 1.8 mg/kg respectively in mice. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 55 mg/mL (125.74 mM), Sonication is recommended.
|
| Keywords | Tigemonam |
| Inhibitors Related | Neomycin sulfate | Adipic dihydrazide | Levulinic acid | D(+)-Raffinose pentahydrate | Sulfamethoxazole sodium | Terbinafine hydrochloride | Doxycycline | Hyaluronic acid sodium (MW 20 kDa) | Dimethyl sulfoxide | Sodium diacetate | Sodium bicarbonate | BES |
| Related Compound Libraries | Bioactive Compound Library | ReFRAME Related Library | Anti-Gram-Negative Bacterial Library | Beta-Lactam Compound Library | Anti-Bacterial Compound Library | Bioactive Compounds Library Max | Anti-Infection Compound Library | Human Metabolite Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$553.00
|
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-04-27 |
United States